4//SEC Filing
Gheuens Sarah 4
Accession 0001439222-25-000082
CIK 0001439222other
Filed
Jul 10, 8:00 PM ET
Accepted
Jul 11, 4:59 PM ET
Size
10.8 KB
Accession
0001439222-25-000082
Insider Transaction Report
Form 4
Gheuens Sarah
Chief Medical Officer
Transactions
- Exercise/Conversion
Common stock
2025-07-09$25.01/sh+11,914$297,969→ 73,185 total - Exercise/Conversion
Stock options (right to buy)
2025-07-09−11,914→ 32,086 totalExercise: $25.01Exp: 2033-03-01→ Common stock (11,914 underlying) - Sale
Common stock
2025-07-09$37.93/sh−11,067$419,771→ 62,118 total - Sale
Common stock
2025-07-09$38.76/sh−847$32,830→ 61,271 total
Footnotes (4)
- [F1]This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
- [F2]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $37.52 to $38.49. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F3]The price reported is the weighted average of the shares sold. The shares were sold at varying prices in the range of $38.55 to $38.87. The reporting person undertakes, upon request by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
- [F4]This option was originally granted on March 1, 2023 for the purchase of 44,000 shares of common stock. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.
Documents
Issuer
AGIOS PHARMACEUTICALS, INC.
CIK 0001439222
Entity typeother
Related Parties
1- filerCIK 0001881190
Filing Metadata
- Form type
- 4
- Filed
- Jul 10, 8:00 PM ET
- Accepted
- Jul 11, 4:59 PM ET
- Size
- 10.8 KB